Polyrizon的PL-14过敏阻隔剂鼻腔凝胶显示,初步人类试验取得了积极的安全结果。 Polyrizon's PL-14 Allergy Blocker nasal gel shows positive safety results in preliminary human trials.

一家生物技术公司Polyrizon报告了其PL-14过敏屏蔽器的初步安全结果,这是用来阻塞空气中过敏原的鼻胶喷雾。 Polyrizon, a biotech firm, has reported positive preliminary safety results for its PL-14 Allergy Blocker, a nasal gel spray designed to block airborne allergens. 对人体鼻腔组织进行的研究显示,该产品具有良好的授标性,不会损害组织功能。 The study, conducted on human nasal tissue, showed the product is well-tolerated and does not impair tissue function. 这些成果为定于2025年底或2026年初举行的林业发展局会议和临床试验提供支持。 These results support upcoming FDA meetings and clinical trials planned for late 2025 or early 2026.